Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Pfizer/BioNTech Send In Data For Booster Approval

Plus A Shortage Of COVID-19 Treatment

Executive Summary

Pfizer and BioNTech sent in Phase I data for a third dose of BNT162b2 to support future licensure, Gritstone bio will work with CEPI to develop its second-generation vaccine in South Africa and other areas, and Roche Genentech expects a shortage of the drug Actemra to last for several weeks amid a surge in cases.

You may also be interested in...



COVID-19-Induced Actemra Shortage Causes Headaches For CAR-T Centers

While some cancer centers report sufficient stocks of the drug, they have already been turning to potential alternatives due to supply issues that could last for weeks or months.

Coronavirus Update: FDA Approves Pfizer/BioNTech's Comirnaty

The FDA granted an expected, though long-awaited, approval to the COVID-19 vaccine. Also, Korean regulators have begun a review of Russian vaccine CoviVac, while Bavarian Nordic has initiated a Phase II study of its vaccine booster candidate and received a commitment for up to DKK 800m from the Danish government.

COVID-19 Vaccines: Updated FDA EUA Gave CDC Wiggle Room In Defining Population For Third Shot

Updated EUA for mRNA COVID-19 vaccines left CDC room to define the type of conditions that meet the immunocompromised level described by the FDA. The recommendation for a third shot for immunocompromised patients was based on small studies using surrogates for vaccine efficacy, not hard clinical outcomes. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel